cannabis
CRISPR Cannabis Patient Benefit vs Standard Cannabinoids: Who Wins?
In 2023, a double-blind trial showed an 18% greater pain reduction for standard high-CBD/THC blends than for CRISPR-edited cannabis, indicating conventional cannabinoids currently win the efficacy battle. Researchers tout CRISPR’s ability to lock in analgesic profiles, but mixed trial outcomes and patient reports raise doubts. Medical Disclaimer: This